Otology & Neurotology Group CTS495, Department of Genomic Medicine, GENYO - Centre for Genomics and Oncological Research - Pfizer/University of Granada/Junta de Andalucía, PTS, 18016, Granada, Spain.
Department of Otolaryngology, Complejo Hospitalario Universidad de Granada (CHUGRA), ibs.granada, 18014, Granada, Spain.
Hum Genomics. 2017 May 22;11(1):11. doi: 10.1186/s40246-017-0107-5.
The identification of disease-causing variants in autosomal dominant diseases using exome-sequencing data remains a difficult task in small pedigrees. We combined several strategies to improve filtering and prioritizing of heterozygous variants using exome-sequencing datasets in familial Meniere disease: an in-house Pathogenic Variant (PAVAR) score, the Variant Annotation Analysis and Search Tool (VAAST-Phevor), Exomiser-v2, CADD, and FATHMM. We also validated the method by a benchmarking procedure including causal mutations in synthetic exome datasets.
PAVAR and VAAST were able to select the same sets of candidate variants independently of the studied disease. In contrast, Exomiser V2 and VAAST-Phevor had a variable correlation depending on the phenotypic information available for the disease on each family. Nevertheless, all the selected diseases ranked a limited number of concordant variants in the top 10 ranking, using the three systems or other combined algorithm such as CADD or FATHMM. Benchmarking analyses confirmed that the combination of systems with different approaches improves the prediction of candidate variants compared with the use of a single method. The overall efficiency of combined tools ranges between 68 and 71% in the top 10 ranked variants.
Our pipeline prioritizes a short list of heterozygous variants in exome datasets based on the top 10 concordant variants combining multiple systems.
使用外显子组测序数据鉴定常染色体显性疾病中的致病变异仍然是小家族中的一项艰巨任务。我们结合了几种策略,使用家族性梅尼埃病的外显子组测序数据集来改进杂合变异的过滤和优先级排序:内部致病性变异 (PAVAR) 评分、变体注释分析和搜索工具 (VAAST-Phevor)、Exomiser-v2、CADD 和 FATHMM。我们还通过包括合成外显子数据集中的因果突变的基准测试程序验证了该方法。
PAVAR 和 VAAST 能够独立于研究疾病选择相同的候选变异集。相比之下,Exomiser V2 和 VAAST-Phevor 取决于每个家族中疾病的可用表型信息,相关性不同。然而,使用三种系统或其他组合算法(如 CADD 或 FATHMM),所有选定的疾病在前 10 名排名中都将数量有限的一致变异排在前 10 位。基准分析证实,与使用单一方法相比,具有不同方法的系统组合可提高候选变异的预测能力。组合工具的整体效率在排名前 10 的变异中介于 68%和 71%之间。
我们的管道基于前 10 个一致的变体,使用多个系统对来自外显子组数据集的杂合变体进行优先级排序,生成一个简短的列表。